January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
Jan 6, 2026, 09:30

Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

”Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B: The Subgroup (N=33) With No Neutralizing Anti-AAV Antibodies (NAb-Negative):

  • 100% expressed endogenous FIX at therapeutic levels (mean 39.0 IU/dL)
  • 100% remained prophylaxis-free over 4 years—zero returned to prophylaxis
  • Exogenous FIX consumption decreased by 99%
  • 85% reduction in bleeds (all, spontaneous, joint)​
  • Safety: Treatment-related AEs only first 3 months; transient ALT elevations 18%, all manageable​

This enables direct comparison to other haemophilia B gene therapies where only NAb-negative patients were enrolled.​

HOPE-B’s Inclusive Design

HOPE-B is the first—and currently only—haemophilia B gene therapy trial to include patients with pre-existing AAV neutralizing antibodies for treatment with etranacogene dezaparvovec.

Very recently, the NEJM paper presented 5-year data of the full cohort (NAb-negative and NAb-positive; N=54).​

Congratulations to Priyanka Raheja and co-authors!”

Read the full article here.

Article: Etranacogene dezaparvovec in participants with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: A 4-year subgroup analysis (HOPE-B)

Authors: Priyanka Raheja, Niamh O’Connell, Peter Verhamme, Peter Kampmann, Richard S. Lemons, Fei Wang, Sean Gill, Paul E. Monahan, Sandra Le Quellec, Frank W. G. Leebeek

Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B

Stay updated on all scientific advances with Hemostasis Today.